1. Advanced glycation end products among patients maintained on antipsychotics
- Author
-
Arij Yehya, Yahya Hani, Hassen Al-Amin, Azza Al-Mujalli, Dennis O. Mook-Kanamori, Marjonneke J. Mook-Kanamori, Karsten Suhre, Samer Hammoudeh, Reem El Sherbiny, Ziyad Mahfoud, Suhaila Ghuloum, and Abdulmoneim Abdulhakam
- Subjects
Adult ,Glycation End Products, Advanced ,Male ,medicine.medical_specialty ,Adolescent ,Cross-sectional study ,Population ,030209 endocrinology & metabolism ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Glycation ,Internal medicine ,Statistical significance ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Young adult ,education ,Aged ,Skin ,education.field_of_study ,business.industry ,Case-control study ,Middle Aged ,Psychiatry and Mental health ,Cross-Sectional Studies ,Sample size determination ,Case-Control Studies ,Female ,business ,030217 neurology & neurosurgery ,Antipsychotic Agents - Abstract
The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded. Among the group maintained on antipsychotics, women, smokers, and Arabs had significantly higher AGEs levels compared with men, nonsmokers, and non-Arabs, respectively (P
- Published
- 2017
- Full Text
- View/download PDF